Immunotherapy is now incorporated into National Comprehensive Cancer Network guidelines as maintenance therapy and in a sequencing strategy for the treatment of patients with metastatic urothelial carcinoma and in the setting of superficial UC-carcinoma in situ with prior intravesical therapy.
Immunotherapy is now incorporated into National Comprehensive Cancer Network (NCCN) guidelines as maintenance therapy and in a sequencing strategy for the treatment of patients with metastatic urothelial carcinoma (UC) and in the setting of superficial UC-carcinoma in situ (CIS) with prior intravesical therapy.1
Version 1.2021 of the guidelines lists avelumab (Bavencio) as a category 1 preferred maintenance option for patients with cisplatin-eligible and cisplatin-ineligible locally advanced or metastatic (stage IV) bladder cancer. The inclusion is based on data demonstrating an overall survival (OS) advantage to avelumab maintenance plus best supportive care (BSC) in patients with advanced urothelial cancer that had not progressed on frontline platinum therapy compared with BSC alone in the phase 3 JAVELIN Bladder 100 trial2, explained Arlene O. Siefker-Radtke, MD, in a presentation during the 2021 NCCN Virtual Annual Conference.
In JAVELIN Bladder 100, the addition of avelumab to BSC as maintenance improved the median OS from 14.3 months to 21.4 months, corresponding to a significant 31% reduction in the risk of death (HR, 0.69; 95% CI, 0.56-0.86; P = .001).
“Patients who had progressed prior to a 4-week window of starting maintenance avelumab were not included on this trial, so this really looked at patients who had a good response or evidence of benefit to frontline chemotherapy,” said Siefker-Radtke, a professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. JAVELIN Bladder 100 did not allow for crossover to immunotherapy at the time of progression.
Based on these data, the FDA approved avelumab in June 2020 for the maintenance treatment of patients with locally advanced or metastatic UC that has not progressed on first-line platinum-containing chemotherapy.
With the updated NCCN guidelines, patients who have had cisplatin-based or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy who have stable disease or better may receive maintenance avelumab until progressive disease. Maintenance avelumab is also recommended for those with cisplatin-ineligible patients who receive gemcitabine and carboplatin.
Additionally, atezolizumab and pembrolizumab (Keytruda) are options for patients whose tumors express PD-L1 or who are not eligible for platinum-based chemotherapy regardless of PD-L1 expression.
In a double-blind, randomized, phase 2 study, maintenance pembrolizumab following frontline platinum-based chemotherapy, improved progression-free survival at 5.4 months compared with 3.0 months with placebo (HR, 0.65; log-rank P = .0361) compared with placebo in patients with stable or better advanced UC.3 However, it failed to achieve significance on the endpoint of median OS (P = .7477), although median OS was numerically superior in the pembrolizumab arm at 22 months vs 18.7 months with placebo, respectively. Only 108 patients were randomized, so the trial was underpowered to detect a significant difference in median OS, Siefker-Radtke noted.
She then addressed the use of immunotherapy as part of a sequencing strategy in advanced UC. In patients with locally advanced or metastatic UC in whom prior platinum-based chemotherapy has failed, pembrolizumab is now considered the preferred second-line systemic therapy in the NCCN guidelines, with level 1 evidence.
This evidence consists of data from the open-label, international, phase 3 KEYNOTE-045 trial in which 542 patients with advanced UC that recurred or progressed after platinum-based chemotherapy were treated with either pembrolizumab or investigator's choice of single-agent chemotherapy with paclitaxel, docetaxel, or vinflunine. The median OS improved from 7.4 months in the chemotherapy arm to 10.3 months in the pembrolizumab arm (HR, 0.73; 95% CI, 0.59-0.91; P = .002).4 There were also fewer treatment-related adverse events in the immunotherapy arm vs the chemotherapy arm (15.0% vs 49.4%, respectively).
In the second-line setting, the NCCN guidelines include atezolizumab (Tecentriq), nivolumab (Opdivo), and avelumab as alternative preferred checkpoint inhibitors, as well as erdafitinib (specifically in patients with susceptible FGFR3 or FGFR2 alterations).
Durvalumab (Imfinzi) had been included as a second-line strategy, but the PD-L1 inhibitor was voluntarily withdrawn for this indication since it had not met either of its coprimary end points of OS compared between the durvalumab alone vs chemotherapy groups in PD-L1–high patients and between the durvalumab/tremelimumab vs chemotherapy groups in the intent-to-treat (ITT) population in the frontline setting in the DANUBE trial.5
The updated NCCN guideline also lists Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk nonmuscle-invasive bladder cancer as an indication for pembrolizumab, in patients who are ineligible for or have elected not to undergo cystectomy. The rationale for this indication comes from the KEYNOTE-057 study, in which pembrolizumab administered for up to 2 years induced a complete response (CR) rate of 41% and a median duration of CR of 16.2 months in patients with BCG-unresponsive carcinoma in situ with or without papillary tumors.6 The FDA approved pembrolizumab for this indication in January 2020.
In the adjuvant setting, immunotherapy is not yet incorporated into the NCCN guidelines nor is FDA approved, pending OS results from the CheckMate-274 study, in which nivolumab improved disease-free survival vs placebo in patients with high-risk muscle-invasive UC at 21.0 months compared with 10.9 months for the placebo arm in the ITT population (HR, 0.70; 98.31% CI, 0.54-0.89; P <.001).7